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Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal 
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented 
a major therapeutic advance over conventional CML therapy, with more than 90% of patients 
obtaining complete hematologic response, and 70%–80% of patients achieving a complete 
cytogenetic response. Despite the high efficacy of imatinib, a minority of patients in chronic 
phase CML and more patients in advanced phases are resistant to imatinib, or develop resistance 
during treatment. This is attributed, in 40% to 50% of cases, to the development of mutations 
in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent 
resistance led to the discovery of nilotinib (Tasigna), a novel, potent and selective oral Bcr-Abl 
kinase inhibitor.
Aims: To review the evidence for the use of nilotinib in the management of CML.
Evidence review: Preclinical and clinical investigations demonstrate that nilotinib effectively 
overcomes imatinib resistance, and has further improved the treatment of CML.
Place in therapy: Nilotinib is currently indicated for patients with CML in chronic and 
accelerated phases following imatinib failure. Randomized studies are ongoing to assess the 
efficacy of nilotinib in patients with newly diagnosed CML.
Keywords: CML, tyrosine kinase inhibitors, nilotinib, imatinib-resistance, imatinib-
intolerance.
Core evidence place in therapy summary for nilotinib in CML
Outcome measure Evidence Implications
Patient-oriented evidence
Safety and tolerability Clear Nilotinib is well tolerated
Disease-oriented evidence
Cytogenetic response Substantial Nilotinib produces major cytogenetic response in 
31% (accelerated phase), 40% (blastic phase) and 
57% (chronic phase) of patients resistant or intoler-
ant to imatinib. 100% complete response has been 
achieved in newly diagnosed patients
Hematologic response Substantial Nilotinib produces complete hematologic response 
in 11% (blastic phase), 26% (accelerated phase), 
and 77% (chronic phase) of patients resistant or 
intolerant to imatinibCore Evidence 2009:4 208
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Scope, aims, and objectives
Chronic myelogenous leukemia (CML) is characterized 
by a balanced translocation, involving a fusion of the 
Abelson oncogene (ABL) from chromosome 9q34 with the 
breakpoint cluster region (BCR) on chromosome 22q11.2, 
t(9; 22) (q34; q11.2), the Philadelphia chromosome (Ph). 
The molecular consequence of this translocation is the 
generation of a BCR-ABL fusion oncogene, which in turn 
translates into a Bcr-Abl oncoprotein. This most frequently 
has a molecular weight of 210 kD (p210Bcr/Abl) and has 
increased tyrosine kinase activity which is essential to its 
transforming capability.1,2 Imatinib mesylate is a potent and 
selective tyrosine kinase inhibitor that has become standard 
therapy for patients with CML in all stages of the disease.2 
A complete cytogenetic response (CGCR) can be achieved 
in 50% to 60% of patients treated in chronic phase (CP) after 
failure with interferon alpha (IFN-α)3,4 and in over 80% of 
those receiving imatinib as first-line therapy.5,6 Responses 
are durable in most patients treated in early CP, particularly 
among those who achieve major molecular responses (MMR) 
(eg, 3-log reduction in transcript levels).7,8
Despite the excellent results with imatinib in CML, 
resistance to this agent does occur in some cases at an 
annual rate of approximately 4% in newly diagnosed CML, 
but more often in advanced disease.9 Resistance may arise 
in several different ways, including BCR-ABL-dependent 
and BCR-ABL-independent mechanisms. BCR-ABL kinase 
domain point mutations are often associated with imatinib 
resistance. These mutations impair imatinib activity, for 
example by interfering with an imatinib binding site or by 
stabilizing a conformation of BCR-ABL with reduced affinity 
to imatinib.10,11 BCR-ABL kinase domain mutations vary in 
the extent to which they block imatinib binding and induce 
resistance to this drug.12,13
Several approaches have been investigated to overcome 
resistance to imatinib, including the development of new, 
more potent tyrosine kinase inhibitors (TKIs).14 Examples of 
such inhibitors include nilotinib (Tasigna),15 dasatinib,16 and 
other TKIs under clinical investigation such as bosutinib17 
and INNO-406.18 Herein we review the currently available 
data with nilotinib, including preclinical findings, pharmaco-
kinetic data, results from phase I and II trials, possible indi-
cations beyond CML, and potential for use in combination 
therapy.
Structure
Nilotinib was developed using a rational design strategy 
based on the premise that Bcr-Abl inhibitors more potent and 
selective than imatinib could be developed by making modest 
changes in this molecule.15 Analysis of the structure of imatinib 
and that of the Abl kinase domain indicated that changes to 
the structure’s part that binds deep into the ATP-binding 
pocket would be likely to decrease its efficacy, but that modi-
fication of the methylpiperazinyl group of imatinib that lies 
along a partially hydrophobic group on the surface of Abl 
kinase might improve binding characteristics. Substitutions 
in this ring system resulted in the discovery of nilotinib, 
which is structurally similar to imatinib (Figure 1).19
In vitro studies
Results from in vitro studies have demonstrated that nilotinib 
is more potent than imatinib in inhibiting Bcr-Abl tyrosine 
kinase activity in cell lines and that it is at least 10-to 30-fold 
more potent than imatinib in inhibiting proliferation of 
Bcr-Abl-expressing cells. Inhibition of cell growth by 
nilotinib was associated with induction of apoptosis, but it 
did not decrease the formation of normal human myeloid and 
erythroid progenitor cells at concentrations 100 nM.15
Nilotinib effectively inhibited proliferation of Ba/F3 
cells stably expressing point mutations (E255V, F317L, 
M351T, F486S, G250E, M244V, L248R, Q252H, Y253H, 
E255K, E279K, E282D, V289S, and L384M) associated 
with imatinib resistance in patients (Figure 2). However, 
the T315I mutant remained resistant to nilotinib at con-
centrations 10 µM.15,20 Nilotinib also potently inhibited 
tyrosine autophosphorylation of the E255K, E255V, F317L, 
M351T, and F486S Bcr-Abl mutants, and these effects were 
not associated with decreases in Abl or Bcr-Abl protein 
levels. Overall, these results supported the conclusion that 
many imatinib-resistant Bcr-Abl mutants were relatively or 
absolutely more sensitive to nilotinib.21
Nilotinib also inhibits to a lesser extent platelet-derived 
growth factor receptor (PDGFR-alpha) and PDGFR-beta, 
as well as c-kit dependent cell proliferation. In contrast, 
imatinib has more potency against PDGFR and c-kit than 
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Abl. Nilotinib has no significant activity against other kinases 
evaluated at concentrations 3000 nM.19
Studies investigating the induction of mutants after 
exposure to imatinib under conditions that favor mutagen-
esis using a cell-based screen indicated that resistance to 
nilotinib was associated with a limited spectrum of Bcr-Abl 
kinase mutations, mostly affecting the P-loop and T315I. 
With the exception of T315I, all of the mutations identified 
in one study were effectively suppressed when the nilotinib 
concentration was increased to 2000 nM, which is within 
the trough-peak range for plasma levels (1.7–3.6 µM) 
measured in patients treated with nilotinib 400 mg twice 
daily.15,22 These results support the view that the clinical use 
of nilotinib has relatively low potential to result in significant 
resistance development by Bcr-Abl-expressing cells.22 Ray 
and colleagues have recently reported in a random muta-
genesis screen on six mutations (L248V, Q252H, Y253H, 
Y253C, E255K, and T315I) that can recover after nilotinib 
incubation;23 these mutations have been previously reported 
in patients receiving imatinib. However, the authors did 
not recover other clinically identified mutants that confer 
imatinib resistance (eg, E255V, Y253F, or T315S/G).23
Additive/synergistic activity has been reported following 
the coadministration of imatinib and nilotinib in a panel of 
wild type and imatinib-resistant Bcr-Abl-expressing cell 
lines.24 This additive activity was confirmed in vivo in mice 
harboring murine 32D p210 cells. Mice treated with both 
agents were observed to carry lower tumor burden than mice 
treated with each agent alone.24
In vivo studies
The efficacy of nilotinib has been documented in in vivo 
models of CML, such as mice with Bcr-Abl-positive 
leukemias, both imatinib-sensitive and resistant. In both of 
these models, treatment with nilotinib significantly decreased 
tumor burden and prolonged survival relative to vehicle.15
Pharmacokinetics
Results from pharmacokinetic studies in Balb/c mice given 
single doses of nilotinib 20 or 75 mg/kg in 10% NMP/90% 
PEG300 by gavage indicated that the drug was orally bio-
available and well absorbed. These studies also demonstrated 
that nilotinib achieved high concentrations in both the liver 
and bone marrow.15
The pharmacokinetics of nilotinib have been evaluated 
in a phase I dose-escalation study, in which 119 patients 
with imatinib-resistant Ph+ CML or acute lymphoblastic 
leukemia (ALL) received nilotinib as single oral daily 
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Figure 2 Comparison of imatinib and nilotinib (AMN107) iC50 values for blocking proliferation of Ba/F3 cells expressing non-mutated Bcr-Abl or kinase domain mutated 
Bcr-Abl.15 Copyright © 2005, Elsevier. reproduced with permission from weisberg E, Manley Pw, Breitenstein w, et al. Characterization of AMN107, a selective inhibitor of 
native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141.
Notes: Solid gray bars indicate imatinib iC50 values, and solid red bars indicate nilotinib (AMN107) iC50 values. Dotted black line indicates the mean trough plasma level of 
imatinib reported in patients 24 hours following treatment with a once-daily dose of 400 mg.Core Evidence 2009:4 210
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doses of 50, 100, 200, 400, 800, or 1200 mg, or twice-daily 
doses of 400 or 600 mg.25 The median time to peak serum 
concentrations of nilotinib was three hours and the mean 
peak concentration at steady state (achieved at day 8) in 
patients administered 400 mg twice daily was 3.6 µM. 
Nilotinib had an apparent half-life of 15 hours. There was 
a 2–3-fold increase in exposure to nilotinib between the 
first dose and steady state. Peak concentration and area 
under the serum concentration-time curve at steady state 
increased with dose from 50 to 400 mg and reached a 
plateau with doses greater than 400 mg. Nonlinearity with 
higher nilotinib doses is thought to result from saturation 
of gastrointestinal absorption; nilotinib 400 mg twice 
daily resulted in steady-state exposure greater than that 
observed with a single daily 800 mg dose.25 Based on these 
data, twice daily dosing was selected for phase II studies 
of nilotinib.
Clinical evidence with nilotinib  
in CML
Efficacy
The phase I study of nilotinib included 119 patients with 
imatinib-resistant or intolerant Ph+ CML or ALL who 
received nilotinib once daily at doses of 50, 100, 200, 400, 
800, or 1200 mg, or 400 or 600 mg twice daily.25 Patients 
in this trial received nilotinib daily unless unacceptable 
adverse events or disease progression occurred. Intrapatient 
dose escalation was permitted in patients with an inadequate 
response and no dose-limiting toxicities (DLTs).
Efficacy results for patients with CML are summarized 
in Table 1. Overall, 39% of 33 patients with blastic phase 
CML achieved a hematologic response (HR), and 27% 
a cytogenetic response. Among 46 patients with accelerated 
phase CML, excluding those with clonal evolution, 72% 
achieved a HR, and 48% had a cytogenetic response, 
including a major cytogenetic response in 20%. Six of 
10 patients with clonal evolution achieved a major cyto-
genetic response. Of 17 patients with chronic phase CML, 
92% of 12 patients with active disease achieved complete 
hematologic response (CHR) and cytogenetic response was 
noted in 53% (complete in 35%) (Table 1).26
Fifty-one Abl kinase domain mutations were observed 
in 37 (41%) of 91 patients who were assessed at baseline. 
Hematologic and cytogenetic responses were similar in 
patients with or without mutations and in patients with p-loop 
or other mutations. The two patients with a T315I mutation 
did not respond to nilotinib.26
The efficacy of nilotinib was confirmed in three ongoing 
phase II studies in imatinib-resistant or intolerant patients 
with CML in chronic, accelerated, and blastic phases 
(Table 2).27–30
Three hundred twenty one patients with chronic phase 
CML (71% imatinib-resistant; 21% imatinib-intolerant) 
treated with nilotinib were evaluable.27 Nilotinib was 
given at the dose of 400 mg twice daily, on an empty 
stomach, and escalated to 600 mg twice daily for inadequate 
responses. Complete hematologic response was reported 
in 158 of 206 patients with active disease at the beginning 
(77%). Overall, the major cytogenetic response rate was 
57%; 41% had a complete cytogenetic response. Major 
cytogenetic responses were observed in 125 (55%) of the 
227 imatinib-resistant patients and in 59 (63%) of the 94 
imatinib-intolerant patients. The median time to complete 
hematologic response and major cytogenetic response was 
1.0 and 2.8 months, respectively. The majority of patients 
(84%) maintained the major cytogenetic response for at 
least 18 months. The estimated 18-month overall survival 
rate was 91%.
Table 1 Phase i hematologic and cytogenetic responses to nilotinib in patients with CML
No. (%) Hematologic response No. (%) Cytogenetic response
Results in CML transformation Total/activea CHR MR RTC Overall CR PR Minor Minimal Major Overall
Accelerated phase
  – Hematologic disease 46 21 3 9 33 (72) 6 3 4 9 9 (20) 22 (48)
  – Clonal evolution onlyb 10/5 5 – – 5 (100) 2 4 1 2 6 (60) 9 (90)
Total 56/51 26 3 9 38 (74) 8 7 5 11 15 (27) 31 (55)
Blastic phase
  – Myeloid 24 2 2 6 10 (42) 1 4 2 – (21) (29)
  – Lymphoid 9 – 1 2 3 (33) 1 – – 1 (11) (22)
Total 33 2 3 8 13 (39) 2 4 2 1 6 (18) 9 (27)
Notes: aPatients with hematologic manifestation of disease (ie, not CHr); bPatients whose only criteria for accelerated phase was clonal evolution.
Abbreviations: CHr, complete hematologic response; Cr, cytogenetic response; Mr molecular response; rTC, return to chronic phase.Core Evidence 2009:4 211
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In another study, 136 patients with accelerated phase 
CML received nilotinib at the dose of 400 mg twice daily for 
a median duration of 210 days.28 A confirmed hematologic 
response occurred in 69/129 patients (54%); 26% had a 
complete hematologic response. Major cytogenetic responses 
occurred in 40/129 patients (31%); 24/129 patients (19%) had 
complete cytogenetic responses. Thirty out of 104 patients 
(29%) of imatinib-resistant patients and 10/25 imatinib-
intolerant patients (40%), had a major cytogenetic response. 
Time to first hematologic response and major cytogenetic 
response was 1 and 2.8 months, respectively. The estimated 
12-month progression free and overall survival rates were 
57% and 81%, respectively.
In the third trial, 136 patients with blastic phase disease 
(myeloid, n = 105; lymphoid, n = 31) were treated with 
nilotinib 400 mg twice daily.29 The hematologic response rate 
was 21% and 11% achieved complete hematologic response. 
Major cytogenetic response was achieved in 55 patients 
(40%), and 40 (29%) had complete cytogenetic response. The 
estimated 12-month overall survival rate was 42%.
Safety
In the phase I trial of nilotinib the maximum tolerated dose 
(MTD), defined as the highest dose given for at least 1 cycle 
in which 33% experienced a DLT, was 600 mg twice daily.24 
Nilotinib was generally well tolerated. The most common 
hematologic adverse events across all nilotinib doses were 
thrombocytopenia (21%) and neutropenia (14%), mainly 
grade 3 or 4. The frequency of both appeared to increase 
with nilotinib dose.25 Rash and pruritus were the most 
common nonhematologic adverse events (20% and 15% of 
patients, respectively), but were almost all grade 1 or 2.25 
The most common laboratory abnormalities were elevations 
in bilirubin (7% grade 1 or 2, 7% grade 3 or 4), increased 
lipase (5% grade 3 or 4), and increased aspartate transaminase 
(AST) and/or alanine transaminase (ALT) (1% grade 1 or 2 
and 3% grade 3 or 4).25 The frequency and grade of bilirubin 
elevations increased with nilotinib dose, but these rises were 
generally self-limiting and resolved with continued adminis-
tration of nilotinib.25 Analysis of electrocardiograms (ECGs) 
indicated one instance of increased QTcF (5–15 msec). One 
patient had two treatment-related adverse cardiac events 
(grade 1 pericardial effusion and grade 2 atrial fibrillation).25
In all three phase II studies, nilotinib was well tolerated. 
The rate of grade 3–4 neutropenia was 13% in patients 
with chronic phase, 18% in accelerated phase, and 25% 
in blastic phase and Ph+ ALL. The corresponding rates of 
grade 3–4 thrombocytopenia were 13%, 27%, and 29%. 
Nonhematologic side effects were infrequent and usually 
grade 1–2. These included fatigue, pruritus, headache, muscle 
spasms, and gastrointestinal disturbances. Rates of grade 
3–4 hyperbilirubinemia were 8%, lipase elevation 15%, and 
hyperglycemia 13%. For these grade 3–4 adverse events, 
nilotinib was withheld until toxicities recovered to grade 1 
or less, and then resumed at a dose of 400 mg daily. Nilotinib 
was not associated with the common toxic effects seen with 
imatinib such as fluid retention, edema, cramps, and weight 
gain, or with pleural effusions. Nilotinib rarely prolonged the 
QTcF interval. Finally, there was minimal cross intolerance 
between imatinib and nilotinib.30
Frontline therapy
A recent update of a phase II study in patients with newly 
diagnosed chronic phase CML showed that nilotinib 400 mg 
twice daily induces a complete cytogenetic response in nearly 
all patients as early as 3 months after the start of therapy, with 
a favorable toxicity profile. Thirty-five patients have been 
treated for a median of 6.5 months. Complete cytogenetic 
responses were achieved, respectively, in 96% and 100% of 
patients at 3- and 6-month evaluations. The rate of complete 
cytogenetic response at 3, 6, and 12 months compares 
favorably with those observed in historical controls treated 
with imatinib 400 mg or 800 mg daily: at 12 months 100% of 
patients were still in response. Major molecular response was 
Table 2 Phase ii data for nilotinib second-line to imatinib failure
% Response
Cytogenetic response
Disease n CHR Major Complete Overall survival
CML Chronic 321 77 57 41 91% (18 months)
CML Accelerated 136 26 31 19 81% (12 months)
CML Blastic 136 11 40 29 42% (12 months)
Abbreviations: CHr, complete hematologic response; CML, chronic myeloid leukemia.Core Evidence 2009:4 212
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observed in 13% at 3 months, 45% at 6 months, and 45% at 12 
months. Nilotinib showed generally low and manageable 
rates of grades 3/4 adverse events.31
Combination therapy
There is growing interest in testing the hypothesis that 
administration of multiple Abl kinase inhibitors in 
early-phase patients could be used to delay or prevent the 
emergence of drug-resistant clones.32 The combination of 
two agents targeting different pathways involved in CML 
may significantly improve response rates and potentially 
increase survival.
Support for this concept is provided by preliminary 
preclinical investigations of the imatinib–nilotinib 
combination.24 Additive/synergistic toxicity against both 
imatinib-sensitive and imatinib-resistant Bcr-Abl-expressing 
cells has been reported following coadministration of 
nilotinib and imatinib, in vitro and in vivo.15,24 This 
cooperative activity could result from pharmacodynamic 
interactions with cell transporters. Preliminary data suggest 
that synergy between imatinib and nilotinib may occur at the 
level of the CML stem cell due to the ability of both imatinib 
and nilotinib to inhibit or act as substrates of the multidrug 
efflux transporter Abcg2, which confers resistance toward 
several anticancer drugs.33 It is also reported that imatinib and 
nilotinib might be taken up in cells by different mechanisms, 
with the influx, intracellular concentrations of imatinib, and 
consequently patient sensitivity to imatinib depending upon 
the organic cation transporter (OCT-1), whereas nilotinib 
transport appears to be independent of OCT-1.34
Both nilotinib and dasatinib efficiently block Bcr-Abl 
tyrosine kinase catalytic activity by binding to distinct, par-
tially overlapping sites in the kinase domain. Cross resistance 
with dasatinib is limited to T315I, which is also the only 
mutant isolated at drug concentrations equivalent to maximal 
achievable plasma trough levels.20 With drug combinations, 
maximal suppression of resistant clone outgrowth was 
achieved at lower concentrations compared with single agents, 
suggesting that such combinations may be equipotent to higher 
dose single agents. A combination of low doses of dasatinib 
and low doses of nilotinib may effectively suppress the emer-
gence of mutations other than T315I with an acceptable safety 
profile.35,36 This approach needs to be eventually extended to 
include specific inhibitors of T315I Bcr-Abl kinase domain 
mutations. Alternatively, it is also important to explore the 
potential for synergy between nilotinib and other classes of 
inhibitors that work through mechanisms not involving inhibi-
tion of Abl tyrosine kinase activity.37,38
Finally, long-term treatment of CML may require 
a  combination  of  both  conventional  and  targeted 
compounds such as tyrosine kinase inhibitors, farnesyl 
transferase inhibitors, and possibly compounds with other 
mechanisms of action like vaccines, to stimulate patient 
immunity and possibly control and eliminate residual 
disease.
Place of nilotinib in CML therapy
Imatinib has benefited a large number of patients with 
CML. However, imatinib resistance has emerged as an 
important clinical challenge. Novel treatment strategies 
have been investigated after failure of imatinib therapy. 
The availability of highly potent tyrosine kinase inhibitors, 
such as nilotinib, has broadened the treatment armamen-
tarium in CML. Nilotinib appears to overcome imatinib 
resistance in patients with chronic, accelerated, and blastic 
phase CML, producing sustained cytogenetic and hemato-
logical responses. Combination strategies may be useful, 
although these have not yet been examined in clinical 
studies. With the availability of nilotinib, treatment options 
are increasing in CML, and this is likely to continue in the 
future.
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